Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.66 |
| ▸ | MGLL | Q99685 | 2/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | RBP4 | P02753 | 2/20 | 0.54 |
| ▸ | SCD | O00767 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238339 | 0.92 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL3661780 | 0.92 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL29783896 | 0.84 | CYP2C9 (0.68) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL21740905 | 0.83 | CYP2C9 (0.63) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL10304326 | 0.81 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL23573376 | 0.81 | CYP2C9 (0.64) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL4262448 | 0.80 | CYP2C9 (0.63) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL2006284 | 0.80 | CYP2C9 (0.59) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL17946287 | 0.80 | MEN1 (0.65) | CYP2C9CYP2C19MAPK14MGLLHSD11B1 | |
| SCHEMBL4635407 | 0.79 | CYP2C9 (0.52) | CYP2C9CYP2C19HTR2BMAPK14MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | CYP2C9 1693/4885CYP2C19 2909/4885HTR2B 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.